BRSK2 Antibodies

Serine/threonine-protein kinase BRSK2 (BRSK2)

Serine/threonine-protein kinase that plays an integral role in polarization of neurons and axonogenesis, cell cycle progress and insulin secretion. After phosphorylation and activation by STK11/LKB1, functions as a key regulator of polarization of cortical neurons, probably by mediating phosphorylation of microtubule-associated proteins like MAPT/TAU in'Thr-529' and'Ser-579'.

Also regulates neuron polarization by mediating phosphorylation of WEE1 in'Ser-642' in postmitotic neurons, leading to down-regulate WEE1 action in polarized neurons. Plays a role in the regulation of the mitotic cell cycle progress and the onset of mitosis.

Gene Information

Human
Gene Name:	BRSK2
Uniprot:	Q8IWQ3
Entrez:	9024

Family

Belongs to:
protein kinase superfamily

Alternative Names

BR serine/threonine kinase 2; BR serine/threonine-protein kinase 2; C11orf7; chromsosome 11 open reading frame 7; EC 2.7.11; EC 2.7.11.1; FLJ41362; PEN11BSAD1; protein kinase SAD1B; serine/threonine kinase 29; serine/threonine kinase SAD-A; Serine/threonine-protein kinase 29; Serine/threonine-protein kinase SAD-A; STK29

Molecular Weight

Mass (kDA):
81.633 kDA

Genomic Context

Human
Location:	11p15.5
Sequence:	11; NC_000011.10 (1389934..1462689)

Tissue Specificity

Detected in pancreas islets (at protein level).

Subcellular Localizations

Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, perinuclear region. Endoplasmic reticulum. Detected at centrosomes during mitosis. Localizes to the endoplasmic reticulum in response to stress caused by tunicamycin.

Diseases

• Neoplasms
• Cell Invasion
• Adenocarcinoma
• Neoplasm Metastasis
• Pancreatic Ductal Adenocarcinoma
• Lung Neoplasms
• Melanoma
• Paraneoplastic Syndromes, Nervous System
• Malignant Neoplasm Of Lung
• Endoplasmic Reticulum Stress
• Lymphatic Metastasis
• Small Cell Carcinoma Of Lung

• Malignant Neoplasms
• Carcinoma, Pancreatic Ductal
• Encephalitis
• Pancreatic Neoplasm
• Limbic Encephalitis
• Ductal Breast Carcinoma

Pathways

• Cell Cycle
• Insulin Secretion
• Mitosis
• Cell Cycle Arrest
• Secretion
• G1 Phase
• Cell Growth
• Exocytosis

• Energy Homeostasis
• Pathogenesis
• Localization

PTMs

• Phosphorylation
• Cleavage

• Dephosphorylation
• Palmitoylation

• Ubiquitination

Research Areas

• Immune System Diseases
• Immunology
• Protein Kinase

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BRSK2

Best Uses Of The BRSK2 Marker

BRSK2 is a novel marker that has several applications in molecular diagnostics. The company, whose main product is an ELISA kit for detection of this protein, collaborated with Ono Pharmaceutical and Abbvie Inc. in order to create a better detection method. This patented technology can detect the protein in a single cell, or it can be used to detect multiple targets simultaneously.

ELISA kits for detection of NTRK2, PTN and NTN1

ELISA kits for detection of NTRKK2, PTN, and NTN1 have become a popular choice for many researchers, because they are cost-effective and time-saving. However, not all assay kits are created equal. Some fail to provide biologically relevant sensitivity, while others fail to demonstrate the reproducibility required for long-term studies. Purchasing a convenient kit could ultimately cost you more time and money than it's worth.

ELISA kits for detection of NTRKK1, NTN1, and PTN1 were evaluated against serum samples of individuals with and without malaria. The kits were evaluated based on sensitivity, specificity, and cross-reactivity, and their ease of use was compared to other commercially available ELISA kits. Compared to these, three out of the five kits were judged as being user-friendly. Among them, the NovaTec kit was deemed to be the most user-friendly.

ELISA kits for detection of NTN1 allow quantification of the protein in serum, plasma, or tissue homogenates. The kit's recovery rate is calculated by comparing the measured value to the expected amount of NTN1 in samples. Serial dilutions and spiked samples were used to verify that the kit's linearity could be measured. The percentage of predicted concentration to the measured value was within 1% of the expected level.

The optimal ELISA kit would use DBS to maintain high accuracy while reducing costs. However, commercial ELISA kits are expensive and the technician's time is a factor. This means that RB-ELISA kits are an excellent option for researchers who need to monitor the presence of NTRK2, PTN, and NTN1 in a sample. However, RB-ELISA kits are not as sensitive as commercially available ELISAs.

Using a commercial ELISA kit, we calculated the seropositivity threshold using a two-Gaussian mixture model. This criterion defined seropositivity as three standard deviations from the mean of the lowest Gaussian distribution. In our studies, we used the thresholds determined by the manufacturer's instructions. The results were compared to the corresponding RB-ELISA.

The gene sets are grouped according to their relative expression. Cluster 1 represents genes increased in adult MIA microglia, while clusters 2 and 3 represent those decreased in these cells. In a separate study, we found that MIA inhibited PTN, but had no effect on WNT5A protein. The gene sets were also evaluated in mice undergoing re-treatment of their brains.

Moreover, this research has revealed that CSF1R inhibitor therapy reverses the alterations in microglial cells caused by MIA. Moreover, the inhibitors reversed the increased basal dendritic spine density and enhanced interactions between microglia and neurons. Thus, the results obtained from this study are useful in clinical research. The re-population of microglia and neuronal cells can aid in understanding of the disease.

TI's collaboration with Abbvie Inc.

In an effort to develop and commercialize CD39-targeted cancer drugs, AbbVie has entered into a global strategic collaboration with Tizona Therapeutics. Tizona is a privately held immunotherapy company that has filed for FDA approval of its lead drug candidate TTX-030. The drug's preclinical data suggests that it will inhibit a pathway that prevents cancer cells from releasing adenosine.

The collaboration will include research on immunotherapy and cancer, and the two companies will share their expertise in each area. While both companies have different areas of expertise, AbbVie has specialized strengths in chemistry, automation processes, and generating biological reagents. Yale researchers will benefit from access to AbbVie-developed compounds, including dual-variable-domain antibodies that target two targets at once.

In the Midwest, Epic Systems, an electronic medical records provider, has asked its employees to come back to work after a voluntary leave. This was deemed necessary to preserve the culture of the company. The move sparked employee backlash and questions from the local health department. However, the company is confident in its ability to develop and commercialize COVID-19. However, it does not want to risk sacrificing its reputation as a top-tier pharmaceutical company.

While Dr. Khalid is working on research in the field of immunotherapy, his affiliations include various biopharmaceutical companies. In addition, he has advisory board roles with several companies, including AbbVie. This may be a conflict of interest. Despite these conflicts, the company is still funding the research. In the end, it is the patients that reap the rewards. And with that, the company is also making money.

The collaboration with AbbVie allows AbbVie to expand its global operations to provide end-to-end drug substance and product supply. The company has expanded its Contract Manufacturing offerings to include biologics fill-finish and topical creams. The company has also acquired Allergan and has been recognized for its quality and innovative capabilities by Life Science Leader CMO Awards for the ninth consecutive year.

TI's Ethos platform connects disparate data from different systems. It uses MarkLogic to make it searchable and usable for collaborators. The Ethos suite enables collaborative processes and self-service business process improvement. A single platform provides a powerful collaboration platform and helps businesses collaborate. The Ethos suite also enables teams to share data from multiple systems. For example, the Ethos suite includes the application "Button" for webcams, which allows them to interact with each other and communicate in real time.

AbbVie and Regenxbio will collaborate on an investigational gene therapy called RGX-314. The drug is intended for use in the treatment of diabetic retinopathy and wet AMD. AbbVie will pay $370 million up front to Regenxbio. After the drug has been approved, AbbVie and Regenxbio will split the costs of future studies.

Ono Pharmaceutical's collaboration with TI

Neurimmune AG and Ono Pharmaceutical have signed a new expanded drug discovery collaboration agreement. The new agreement focuses on developing antibody drugs against new therapeutic targets and neurodegenerative diseases. The two companies use unique immuno-oncology therapeutic approaches to develop these drugs. Neurimmune and Ono first announced their collaboration in November 2017.

Ono Pharmaceutical is based in Osaka, Japan. CEO Gyo Sagara leads the company. Together with Iktos, Ono Pharmaceutical will utilize Iktos' AI drug discovery technology. This AI drug discovery technology will allow Ono Pharmaceutical to design and test novel drugs faster and cheaper. Both companies are working on innovative medicines that will provide more patients with better health. To date, the collaboration has resulted in three breakthrough drugs.

The collaboration also involves the development of a new molecule. Ono will receive exclusive rights for both global development and commercialization of the candidate. The collaboration could cost up to 258 million Swiss francs in total. The payments will cover research funding, upfront fees, milestone payments, and tiered royalties on future sales of the drug. In addition, the company will receive an honoraria for lecture fees from companies.